The Science
KMO
at the interface between
inflammation, immunity and metabolism
Kynurenine monooxygenase (KMO) plays a major role in the regulation of inflammation and how the immune system is controlled by inflammation and metabolism. These conditions can be acute, for example critical illness or major surgery, or more long-standing, for example endometriosis and cancers that have evaded the immune system. All these scenarios have a pressing need for new medicines.
KMO inhibitors have the potential to revolutionise the care and outcomes of patients suffering from diseases where inflammation and metabolism meet immunity.
The founding team bring a deep understanding of clinical medicine, disease biology, kynurenine pathway biochemistry and structural biology of KMO, allied to expertise in medicines discovery.
With our lead KMO inhibitor, KNS366, in a first-in-human Phase 1 study, Kynos Therapeutics is pushing forward clinical development of a new generation of potent first-in-class KMO inhibitors with the potential to have a major impact in conditions with high unmet medical need.
address OPERATIONAL HEADQUARTERS
Kynos Therapeutics Ltd.
Enterprise Hub 2.14
Murchison House
King's Buildings
10 Max Born Crescent
Edinburgh EH9 3BF
United Kingdom
phone
email
get-in-touch
To contact Us ,
please use
the form
tnx-msg